Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pfizer Inc (NYSE:PFE)

31.77
Delayed Data
As of Jan 20
 +0.07 / +0.22%
Today’s Change
28.25
Today|||52-Week Range
37.39
-2.19%
Year-to-Date
May's industrial strategy to back 'new, active role' for government
Jan 22 / FT.com - Paid Partner Content
Will This Be a Genius or Foolish Move for Johnson & Johnson?
Jan 13 / MotleyFool.com - Paid Partner Content
BioCorRx Receives New Funding for Opioid Drug
Jan 22 / GuruFocus News - Paid Partner Content
5 Stocks With Bigger Dividends Than ExxonMobil
Jan 13 / MotleyFool.com - Paid Partner Content
Better Buy: Merck & Co. Inc. vs. Pfizer
Jan 22 / MotleyFool.com - Paid Partner Content
ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk
Jan 13 / Zacks.com - Paid Partner Content
How Will Pfizer Inc. Fare Under President Trump?
Jan 21 / MotleyFool.com - Paid Partner Content
It's Full Speed Ahead for Opko Health After Pipeline Stumble
Jan 12 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Gilead Sciences, Las Vegas Sands, Illinois Tool Wo...
Jan 20 / Zacks.com - Paid Partner Content
Trump Attacks Biotech & Pharma: ETFs Bleed
Jan 12 / Zacks.com - Paid Partner Content
Are You Undervaluing These 3 Biopharmas' Pipelines?
Jan 20 / MotleyFool.com - Paid Partner Content
Stock Market News for January 12, 2017
Jan 12 / Zacks.com - Paid Partner Content
Top Analyst Reports for Gilead Sciences, Las Vegas Sands & Illinois Tool Works
Jan 19 / Zacks.com - Paid Partner Content
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
Jan 12 / Zacks.com - Paid Partner Content
Fcm Investments Buys Paycom Software Inc, Alibaba Group Holding Ltd, Enterprise Produ...
Jan 19 / GuruFocus News - Paid Partner Content
Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.
Jan 12 / Zacks.com - Paid Partner Content
Teva's (TEVA) Pain Drug Vantrela ER Receives FDA Approval
Jan 19 / Zacks.com - Paid Partner Content
Drug stocks tumble as Trump singles out pharma companies
Jan 11 / FT.com - Paid Partner Content
Lilly to Boost Migraine Pipeline with $960M CoLucid Buyout
Jan 19 / Zacks.com - Paid Partner Content
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
Jan 11 / Zacks.com - Paid Partner Content
5 Most Important Drugs to Johnson & Johnson in 2017
Jan 18 / MotleyFool.com - Paid Partner Content
3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference
Jan 11 / MotleyFool.com - Paid Partner Content
5 Expensive Drugs That Could End Up in Trump's Crosshairs
Jan 18 / MotleyFool.com - Paid Partner Content
Trump: Drug companies 'getting away with murder'
Jan 11 / CNNMoney.com
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
Jan 18 / Zacks.com - Paid Partner Content
Merck: Keytruda+Chemo Gets Priority Review for Lung Cancer
Jan 11 / Zacks.com - Paid Partner Content
Pfizer warns of 'big challenge' ahead from strong dollar
Jan 18 / FT.com - Paid Partner Content
1 Perfect Stock to Invest in the Pharmaceutical Industry
Jan 10 / MotleyFool.com - Paid Partner Content
Drug companies pledge to improve emerging markets cancer care
Jan 18 / FT.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Clovis Oncology, Pfizer, Roche's, Sanofi and Regen...
Jan 10 / Zacks.com - Paid Partner Content
Gillespie Robinson & Grimm Inc Buys Apple Inc, LKQ Corp, C.R. ...
Jan 17 / GuruFocus News - Paid Partner Content
2 Reasons Pfizer's Stock Beat the Field in 2016
Jan 09 / MotleyFool.com - Paid Partner Content
Pfizer Continues to Tank -- Get Ready to Buy on the Dip
Jan 17 / TheStreet.com - Paid Partner Content
The FDA Approved Fewer Drugs in 2016: Here's Why
Jan 09 / Zacks.com - Paid Partner Content
Should Pfizer, Inc. Be on Your Stock Watchlist?
Jan 17 / MotleyFool.com - Paid Partner Content
Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study
Jan 09 / Zacks.com - Paid Partner Content
Why Bristol-Myers Squibb May Be a Merger Target Soon
Jan 17 / TheStreet.com - Paid Partner Content
2 Top Stocks in Biotech
Jan 09 / MotleyFool.com - Paid Partner Content
One Simple Step to Building a Smarter Portfolio
Jan 17 / MotleyFool.com - Paid Partner Content
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study (Revised)
Jan 09 / Zacks.com - Paid Partner Content
Drugmakers alarmed by Trump pricing threat
Jan 14 / FT.com - Paid Partner Content
Carlyle looks to sell health business Nature's Bounty
Jan 06 / FT.com - Paid Partner Content
Week in Review, January 14
Jan 13 / FT.com - Paid Partner Content